Clinical evaluation of mometasone furoate nasal spray (1st report) - Dose comparison study in Japanese cedar pollenosis

Abstract

The clinical efficacy and safety of 200 μg/day (100 μg b.i.d.) of mometasone furoate nasal spray (MFNS) administered for 2 weeks was evaluated by comparison with a low dose of MFNS of 50 μg/day (50 μg o.d.) using the envelope-method in a total of 65 patients with Japanese cedar pollenosis. The pollen counts for Japanese cedar in 1995 were extremely high in the Kansai district. About 5,000 counts/cm2 was confirmed in and around Osaka. In the analysis of final overall improvement, marked or moderate improvement was observed in 76.2% (16/21) and 20.8% (5/24) of patients receiving MFNS 200 μg/day and 50 μg/day, respectively. The difference in efficacy between the two dosage groups was confirmed independently of timing of the initiation of administration. In the analysis of overall safety, high safety was observed with both treatments. The above results suggest that 200 μg/day of MFNS can be considered the recommended dose for the treatment of Japanese cedar pollenosis.